CKI 7 dihydrochloride: Precision Tool for CK1 Signaling and Cancer Biology Research

Principle and Setup: Targeting Casein Kinase 1 with Precision

CKI 7 dihydrochloride (N-(2-aminoethyl)-5-chloroisoquinoline-8-sulfonamide dihydrochloride) is a potent and selective inhibitor of Casein kinase 1 (CK1), a serine/threonine kinase integral to diverse cellular pathways, including the Wnt/β-catenin pathway, circadian rhythm regulation, and DNA repair. By competitively inhibiting the ATP-binding site of CK1, this cell-permeable CK1 inhibitor for signaling pathway research modulates phosphorylation events critical for cell signaling and disease progression. With a purity of 98% and batch sizes ranging from CKI 7 dihydrochloride 1mg to 50mg, APExBIO ensures researchers can tailor experimental scale to project needs.

CK1-mediated phosphorylation is increasingly recognized as a therapeutic and prognostic nexus, especially in cancer biology and neurobiology research. For instance, recent work demonstrates that the phosphorylation of structural proteins, such as keratins, is central to the metastatic potential of non-small cell lung cancer (NSCLC) cells (Luo et al., 2026). Modulating CK1 activity with specific inhibitors like CKI 7 dihydrochloride empowers researchers to dissect these intricate processes with precision.

Experimental Workflow: Enhanced Protocols for CK1 Inhibition

1. Compound Preparation and Handling

• Stock Solution: Dissolve CKI 7 dihydrochloride in DMSO at up to 17.93 mg/mL; in water, solubility is lower (≤7.17 mg/mL). For most cell-based and biochemical assays, a 10–20 mM solution in DMSO is recommended. Vortex until fully dissolved and filter-sterilize if needed.
• Aliquoting and Storage: For long-term stability, store dry powder at -20°C. Prepare fresh working solutions as needed; avoid repeated freeze-thaw cycles and prolonged storage of solutions to maintain inhibitor potency.

2. Cell-Based Assays for Pathway Dissection

• Wnt/β-catenin Signaling Modulation: Treat cultured cells (e.g., HEK293, HCT116) with CKI 7 dihydrochloride (typically 10–50 μM) to inhibit CK1-mediated phosphorylation of β-catenin. Assay downstream effects via TOPFlash luciferase reporter, immunoblotting for β-catenin, or RT-qPCR for Wnt target genes.
• Apoptosis and Viability Assays: For apoptosis assay using CK1 inhibitors, expose cancer cells to CKI 7 dihydrochloride (10–30 μM) and measure caspase activity, Annexin V/PI staining, or flow cytometry. CK1 inhibition often sensitizes cells to pro-apoptotic stimuli, facilitating cancer biology research with CK1 inhibitors.
• Circadian Rhythm Regulation Studies: In circadian models (e.g., NIH3T3, U2OS PER2::LUC), CKI 7 dihydrochloride modulates clock gene expression and phase-shifts by inhibiting CK1-mediated phosphorylation of PER proteins. Monitor luminescence or gene expression for circadian impacts.

3. Biochemical Assays for Mechanistic Insight

• In Vitro Kinase Assays: Use CKI 7 dihydrochloride (0.5–10 μM) in recombinant CK1 enzyme assays to quantify protein phosphorylation inhibition. Optimize inhibitor concentration for IC50 determination or pathway mapping.
• Protein-Protein Interaction Studies: By modulating CK1 activity, researchers can assess changes in phosphorylation-dependent binding events (e.g., co-immunoprecipitation or proximity ligation assays).

For a detailed, scenario-driven protocol addressing cell viability and cytotoxicity, the article "CKI 7 dihydrochloride (SKU B4936): Reliable CK1 Inhibition in Cell-Based Assays" complements these workflows, offering troubleshooting and real-world application insights.

Advanced Applications and Comparative Advantages

CKI 7 dihydrochloride in Cancer and Circadian Rhythm Research

CKI 7 dihydrochloride is increasingly leveraged in advanced cancer models, including the study of CK1's role in the metastasis of NSCLC. In the 2026 study by Luo et al., phosphorylation events regulated by kinases such as MAPK10 and potentially CK1 were central to keratin 16 (KRT16) proteostasis and cancer cell migration. Using CK1 inhibitors allows researchers to parse the specific contributions of CK1 versus other kinases in phosphorylation-dependent processes, extending translational insights into new biomarkers and therapeutic strategies.

Comparatively, CKI 7 dihydrochloride offers several advantages:

• High Selectivity: Demonstrated minimal off-target effects at working concentrations, enhancing interpretability of cell signaling research.
• Robust Solubility in DMSO: Enables high-concentration stocks for flexibility in assay design (see this resource for comparative solubility data).
• Cell Permeability: Effective in both biochemical and cell-based systems, supporting broad applications from in vitro kinase inhibition to live-cell pathway modulation.
• Batch-to-Batch Consistency: APExBIO provides CKI 7 dihydrochloride in multiple pack sizes (1mg, 5mg, 10mg, 25mg, 50mg), ensuring scalability and reproducibility in experimental workflows.

For researchers focused on pathway dissection, the article "CKI 7 Dihydrochloride: Unraveling Casein Kinase 1 Signaling" extends these findings with case studies in apoptosis assays and Wnt signaling pathway inhibition.

Expanding into Neurobiology and Disease Models

Beyond cancer, CK1 kinase inhibitor compounds like CKI 7 dihydrochloride are pivotal in neurobiology research, where CK1 activity modulates neuronal function, circadian rhythm, and neurodegenerative disease progression. Inhibition of CK1 in Wnt signaling pathway studies has revealed roles in neurodevelopment and synaptic plasticity, with implications for Alzheimer’s and Parkinson’s disease models.

For a deeper mechanistic dive, "CKI 7 dihydrochloride: Advanced Modulation of CK1 Signaling" offers insights into CK1 signaling pathway modulation and biomarker discovery, complementing the present workflow-focused discussion.

Troubleshooting and Optimization Tips

• Solubility Issues: If CKI 7 dihydrochloride does not fully dissolve in DMSO, gently heat to 37°C and vortex. Avoid excessive heating or pH alteration, which may degrade the compound.
• Cytotoxicity Controls: Include DMSO-only and vehicle controls to distinguish CK1 inhibitor-specific effects from solvent background. CKI 7 dihydrochloride is generally well-tolerated at ≤30 μM for 24–48 hours in most cell lines, but always titrate for cell type and endpoint.
• Assay Interference: High DMSO concentrations (>0.5%) can affect cell viability; match solvent concentrations across experimental and control groups. For low-dose applications, consider direct dilution into assay buffer.
• Storage Practices: Store aliquots of solid CKI 7 dihydrochloride at -20°C, protected from moisture and light. Discard working solutions after single use, as repeated freeze-thaw cycles compromise CK1 inhibitor potency and reproducibility.
• Batch Verification: Confirm inhibitor activity with a positive control assay (e.g., CK1-dependent phosphorylation readout) when opening a new lot or scale (1mg, 5mg, 10mg, 25mg, 50mg).

For more detailed troubleshooting strategies, "Strategic Inhibition of Casein Kinase 1: Mechanistic Insights" provides scenario-driven Q&A and practical lab guidance, synergizing with the present article’s hands-on recommendations.

Future Outlook: From Bench to Biomarker and Therapy

Emerging evidence, such as the study by Luo et al. (2026), positions CK1 pathway modulation at the frontier of biomarker and therapeutic discovery. As CK1 inhibitors like CKI 7 dihydrochloride enable precise dissection of phosphorylation events (e.g., in the MAPK10/KRT16/RNF213 axis), they provide a platform for developing targeted therapies and personalized medicine approaches in cancer and beyond.

APExBIO remains committed to supporting next-generation cell signaling research by offering high-purity, well-characterized CK1 inhibitor research chemicals. The ongoing evolution of protein kinase inhibitor toolkits will further enable the study of CK1 in cancer signaling, neurodegenerative diseases, and circadian biology, with CKI 7 dihydrochloride at the forefront of experimental innovation.

For ordering and technical details, visit the dedicated CKI 7 dihydrochloride product page. Whether optimizing apoptosis assays, probing Wnt/β-catenin signaling modulation, or dissecting circadian rhythm regulation, this CK1 inhibitor for research offers reproducible, scalable, and data-driven performance.